Comparative study between effect of both drugs Tamoxifen versus Letrozole on endometrial thickness as Hormonal adjuvant therapy in breast cancer

Khaled Abdallah Jamaan Said Alsaadi; Abdelmonaem Mohamed Zakria; Ahmed Mohamed Mohamed Saeed; Mohamed Salama Mohamed; Wael Abdel Wahab Ghoneim; Marwa Mahmoud Selim; Aalaa Gamil Ibrahim

doi:10.53730/ijhs.v6nS6.13067

Authors

Khaled Abdallah Jamaan Said Alsaadi Departments of surgical oncology in Dar Elsalam Cancer Center and Obstetrics and Gynecology in Faculty of medicine, AL-Azhar University
Abdelmonaem Mohamed Zakria Departments of surgical oncology in Dar Elsalam Cancer Center and Obstetrics and Gynecology in Faculty of medicine, AL-Azhar University
Ahmed Mohamed Mohamed Saeed Departments of surgical oncology in Dar Elsalam Cancer Center and Obstetrics and Gynecology in Faculty of medicine, AL-Azhar University
Mohamed Salama Mohamed Department of Surgical Oncology, National Cancer Institute, Cairo University
Wael Abdel Wahab Ghoneim Department of Surgical Oncology, National Cancer Institute, Cairo University
Marwa Mahmoud Selim
marwaselim_ms@yahoo.com
Department of Medical Oncology, National Cancer Institute, Cairo University
Aalaa Gamil Ibrahim Department of Clinical Oncology, Faculty of medicine, Helwan University

Keywords:

breast cancer, hormonal receptor positive breast cancer, endometrial thickness, tamoxifen, letrozole

Abstract

Background: Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer related death in women. About eighty percent of breast cancers express Estrogen receptors. Long term survival of hormone receptor positive breast cancer patients was significantly improved after introduction of adjuvant hormonal therapy. Different classes of hormonal agents with different mechanisms of action and side effects are available. Tamoxifen has known proliferative effect on endometrium. This may lead to hyperplasia, bleeding and endometrial cancer. Objective: to compare between effects of tamoxifen versus effect of letrozole on the endometrial thickness as adjuvant Endocrine treatment in hormone receptor positive breast cancer. Patients and methods: 66 patients were enrolled in the study from May 2021 to November 2021; they were randomized to receive either tamoxifen or letrozole. Endometrial thickness was measured at baseline, after three and six months from start of treatment. Results: No significant difference in endometrial thickness in the two groups.

Downloads

Download data is not yet available.

References

Abdelaziz A, Shawki M, Mamdoh A, Albarouki S, Rachid A, Alsalhani O, et al. Breast Cancer Awareness among Egyptian Women and the Impact of Caring for Patients with Breast Cancer on Family Caregivers’ Knowledge and Behaviour. Research in Oncology. 2020:1-8.

Cheng W-F, Lin H-H, Torng P-L, Huang S-C. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecologic oncology. 1997;66(2):233-7.

Coates A, Keshaviah A. Thürlimann 3. B, et al Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG.1-98.

Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. British Journal of Surgery. 2018;105(9):1098-106.

Group EBCTC. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet. 2015;386(10001):1341-52.

Jindal A, Mohi MK, Kaur M, Kaur B, Singla R, Singh S. Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy. Journal of mid-life health. 2015;6(2):59-65.

Kim HS, Jeon YT, Kim YB. The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients. Journal of gynecologic oncology. 2008;19(4):256-60.

Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer communications (London, England). 2021;41(11):1183-94.

Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World journal of biological chemistry. 2015;6(3):231.

McDonnell DP, Wardell SE. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Current opinion in pharmacology. 2010;10(6):620-8.

Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Seminars in Oncology. 2003;30:3-11.

Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology. 2003;21(11):2101-9.

Saccardi C, Spagnol G, Bonaldo G, Marchetti M, Tozzi R, Noventa M. New Light on Endometrial Thickness as a Risk Factor of Cancer: What Do Clinicians Need to Know? Cancer management and research. 2022;14:1331-40.

Sharma R. Breast cancer burden in Africa: evidence from GLOBOCAN 2018. Journal of Public Health. 2021;43(4):763-71.

Silva LAS, Felix FB, Araujo JMD, Souza EV, Camargo EA, Grespan R. Agonistic activity of tamoxifen, a selective estrogen-receptor modulator (SERM), on arthritic ovariectomized mice. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2017;51(1):e6799.

Verma S, Sehdev S, Joy A, Madarnas Y, Younus J, Roy JA. An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Current oncology (Toronto, Ont). 2009;16 Suppl 2(Suppl 2):S1-13.